In response to a sharp rise in Mpox infections, the Ministry of Health has announced the arrival of 10,700 doses of the MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) vaccine to aid in containing the outbreak.
This critical intervention follows a 100% increase in Mpox cases since December 31, 2024. “The arrival of the vaccines marks a significant milestone in the national response to interrupt the chain of transmission,” read the Ministry’s statement released on April 9, 2025.
As of now, 67 confirmed cases have been reported across 13 counties, including Busia, Mombasa, Nakuru, and Nairobi. The majority—49 patients—have recovered, while 10 remain hospitalized and one death has been reported. The case fatality rate currently stands at 1.5%.
The vaccine rollout will target high-risk groups such as individuals who’ve had close contact with confirmed cases, long-distance truck drivers, sex workers, and healthcare workers directly involved in patient care. “The deployment will not target the general population, but will prioritize high-risk groups,” the Ministry clarified.
With over 4.1 million travelers screened at 26 points of entry and 485 samples tested, of which 67 turned positive, surveillance remains a top priority.
The Ministry of Health urges the public to take preventive steps, including maintaining hygiene, limiting sexual partners, and self-isolating when symptomatic. “Avoid close contact with suspected or confirmed Mpox cases and sharing personal items,” the advisory added.
“The Mpox vaccination is a demonstration of the Government’s commitment to strengthen health security and ensure the well-being of all Kenyans,” the statement concluded.
